Evidence map›Paper›PMID 42459669›Full record

ArticleFrontiers in immunology2026

TLR7 signaling aggravates lung inflammation associated with increased anti-Scl-70 autoantibody production in murine bleomycin-induced systemic sclerosis.

Jefferson Fernandes Evangelista, Ana Karina Nisperuza Vidal, Donghua Xu, Mohammad Islamuddin, Yilin Chen, Chenxiao Wang, Raul Freitas, Shumei Liu, Elizabeth Engler-Chiurazzi, Robert V Blair and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jefferson Fernandes Evangelista *Division of Comparative Pathology, Tulane National Biomedical Center, Covington, LA, United States.
Ana Karina Nisperuza Vidal *Division of Comparative Pathology, Tulane National Biomedical Center, Covington, LA, United States.
Donghua Xu *Division of Comparative Pathology, Tulane National Biomedical Center, Covington, LA, United States.
Mohammad IslamuddinDivision of Comparative Pathology, Tulane National Biomedical Center, Covington, LA, United States.
Yilin ChenDivision of Comparative Pathology, Tulane National Biomedical Center, Covington, LA, United States.
Chenxiao WangDivision of Comparative Pathology, Tulane National Biomedical Center, Covington, LA, United States.
Raul FreitasDepartment of Neurosurgery and Neurology, Clinical Neuroscience Research Center, Tulane Brain Institute, Tulane University School of Medicine, New Orleans, LA, United States.
Shumei LiuDivision of Comparative Pathology, Tulane National Biomedical Center, Covington, LA, United States.
Elizabeth Engler-ChiurazziDepartment of Neurosurgery and Neurology, Clinical Neuroscience Research Center, Tulane Brain Institute, Tulane University School of Medicine, New Orleans, LA, United States.
Robert V BlairDivision of Comparative Pathology, Tulane National Biomedical Center, Covington, LA, United States.
Prasun K DattaDivision of Comparative Pathology, Tulane National Biomedical Center, Covington, LA, United States.
Xuebin QinDivision of Comparative Pathology, Tulane National Biomedical Center, Covington, LA, United States.

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Role of Complement Activation in Severe COVID-19R01HL165265 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI QIN, XUEBIN · 2022 to 2025
$2.9M
Renal Macrophage BiologyR01DK129881 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI Xuebin Qin · 2022 to 2026
$2.5M
American Heart Association-American Stroke Association 962950NHLBI NIH HHS R01 HL165265NIDDK NIH HHS R01 DK129881NIH HHS P51 OD011104
6 · The paper itself

Abstract

Objective: Systemic sclerosis (SSc) is a severe autoimmune disease characterized by immune dysregulation, fibrosis, and substantial morbidity and mortality. Although type I interferon-related pathways have been implicated in SSc, the contribution of Toll-like receptor 7 (TLR7) and its downstream signaling, including the transcription factor interferon regulatory factor 7 (IRF7) and effector molecules such as CCL2 and CCL12, to disease pathogenesis remains unclear. Methods: We used a bleomycin (BLM)-induced mouse model of SSc. Male wild-type (WT), Results: BLM-treated Conclusion: These findings support a pathogenic role for TLR7-IRF7-IFN-I signaling in anti-Scl-70 autoantibody production and pulmonary inflammation in experimental SSc, and suggest that downstream chemokine pathways may represent therapeutic targets.

Indexed as

AutoantibodiesMembrane GlycoproteinsScleroderma, SystemicToll-Like Receptor 7AnimalsBleomycinChemokine CCL2Disease Models, AnimalInterferon Regulatory Factor-7MaleMiceMice, Inbred C57BLMice, KnockoutSignal TransductionAutoantibodiesBleomycinChemokine CCL2Interferon Regulatory Factor-7Irf7 protein, mouseMembrane GlycoproteinsTlr7 protein, mouseToll-Like Receptor 7anti-Scl-70 antibodiesbleomycinCCL12CCL2CCR2IRF7systemic sclerosisTLR7

Identifiers

PMID42459669
PMCPMC13368542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.